Table 2 Summary of Small Molecule Drugs Involved in Included Studies

CB1R antagonist

SR141716

Rimonabant

168,273-06-1

1.8 nM

C₂₂H₂₁Cl₃N₄O

AM251

–

183,232-66-8

8 nM

C₂₂H₂₁Cl₂IN₄O

AM281

–

202,463-68-1

9.91 nM

C₂₁H₁₉Cl₂IN₄O₂

LH-21

–

611,207-11-5

–

C₂₀H₂₀Cl₃N₃

JD5037

–

1,392,116-14-1

1.5 nM

C₂₇H₂₇Cl₂N₅O₃S

AM6545

–

1,245,626-05-4

1.7 nM

C₂₆H₂₃Cl₂N₅O₃S

SLV319

Bipinabant

464,213-10-3

7.8 nM(Ki)

–

( +)-CBD-HPE

–

–

3.1 nM(Ki)

-

CB2R agonist

HU-308

–

256,934-39-1

22.7 nM(Ki)

C27H42O3

AM1241

–

444,912-48-5

3.4 nM(Ki)

C₂₂H₂₂IN₃O₃

β-Caryophyllene

(–)-trans-Caryophyllene

87-44-5

–

C₁₅H₂₄

LEI-101

–

1,228,660-00-1

7.5 nM(Ki)

C23H25FN4O4S

HU-910

–

–

6 nM(Ki)

/

SMM-295

–

1,054,451–22-7

–

C20H20O2S

JWH-133

–

259,869–55-1

–

C22H32O

CB2R antagonist

AM630

6-Iodopravadoline

164,178–33-0

31.2 nM

C23H25IN2O3

XL-001

–

–

0.5 nM(Ki)

–